The US FDA should clarify the “gray areas” of its four-year-old guidance governing the circumstances under which a drug manufacturer could be considered to be delaying, denying, limiting or refusing a facility inspection, industry attorneys say.
It would help manufacturers and facility owners to get a better idea of FDA’s expectations, such as how quickly agency inspectors should receive documents requested during an inspection before characterizing...